Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
decitabine
- Development stage
- Approved
- Lead developer
- Eisai
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Decitabine is a chemotherapeutic pyrimidine nucleoside analogue used primarily for treating myelodysplastic syndromes (MDS). It works by inducing DNA hypomethylation, which leads to alterations in gene expression. This mechanism helps in reactivating tumor suppressor genes and promoting cellular differentiation or apoptosis in neoplastic cells. Decitabine was developed by MGI Pharma/SuperGen Inc. and approved by the FDA in 2006.
- Brand names
- DacogenInaqoviInqovi
- Other names
- 5-aza-2'-deoxycytidine5-azadeoxycytidine2'-deoxy-5-azacytidine
02
Targets
DNMT3B (DNA (cytosine-5)-methyltransferase 3B)DNMT3A (DNA methyltransferase 3 alpha)DNMT1 (DNA (cytosine-5)-methyltransferase 1)
Beyond the preview
Go deeper on decitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on decitabine.